Publications by authors named "Annette Reboli"

Claim this Profile
A
Accelerated 3YMD programs: the last decade of growth of the Consortium of Accelerated Medical Pathway Programs (CAMPP).
Catherine L Coe, Sally A Santen, Annette C Reboli, Jeffrey R Boscamp, Amanda M Stoltz

Med Educ Online· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are They Prepared? Comparing Intern Milestone Performance of Accelerated 3-Year and 4-Year Medical Graduates.
Sally A Santen, Sandra Yingling, Sean O Hogan, Christina M Vitto, Christin M Traba, Annette C Reboli

Acad Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cooper Medical School of Rowan University.
Susan M Perlis, Rose Kim, Annette C Reboli

Acad Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roadmap for creating an accelerated three-year medical education program.
Shou Ling Leong, Joan Cangiarella, Tonya Fancher, Lisa Dodson, Colleen Grochowski, Annette C Reboli

Med Educ Online· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel.
Cornelius J Clancy, Peter G Pappas, Jose Vazquez, Marc A Judson, Dimitrios P Kontoyiannis, Annette Reboli

Clin Infect Dis· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the Learning Environment for Medical Students: An Evaluation of a Novel Survey Instrument in Four Medical Schools.
Linda H Pololi, Arthur T Evans, Leslie Nickell, Annette C Reboli, Lisa D Coplit

Acad Psychiatry· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
Peter G Pappas, Carol A Kauffman, David R Andes, Cornelius J Clancy, Kieren A Marr, Annette C Reboli

Clin Infect Dis· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
Peter G Pappas, Carol A Kauffman, David R Andes, Cornelius J Clancy, Kieren A Marr, Annette C Reboli

Clin Infect Dis· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008.
Michael A Pfaller, David R Andes, Daniel J Diekema, David L Horn, Annette C Reboli

PLoS One· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and mortality of sepsis, severe sepsis, and septic shock in intensive care unit patients with candidemia.
Kevin Ng, Christa Schorr, Annette C Reboli, Sergio Zanotti, Constantine Tsigrelis

Infect Dis (Lond)· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Micafungin: an evidence-based review of its place in therapy.
Pola de la Torre, Annette C Reboli

Core Evid· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.
Luis Ostrosky-Zeichner, Shmuel Shoham, Jose Vazquez, Annette Reboli, Robert Betts

Clin Infect Dis· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editorial commentary: Is the debate about treatment of Candida parapsilosis complex infections with echinocandins much ado about nothing?
Annette C Reboli

Clin Infect Dis· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial.
Jose Vazquez, Annette C Reboli, Peter G Pappas, Thomas F Patterson, John Reinhardt

BMC Infect Dis· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of central venous catheter-related bloodstream infections: is it time to add simulation training to the prevention bundle?
Amanda R Burden, Marc C Torjman, George E Dy, Jonathan D Jaffe, Jeffrey J Littman, Annette C Reboli

J Clin Anesth· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.
Daniel H Kett, Andrew F Shorr, Annette C Reboli, Arlene L Reisman, Pinaki Biswas

Crit Care· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.
David R Andes, Nasia Safdar, John W Baddley, Geoffrey Playford, Annette C Reboli

Clin Infect Dis· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anidulafungin: when and how? The clinician's view.
Jomy George, Annette C Reboli

Mycoses· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.
Annette C Reboli, Andrew F Shorr, Coleman Rotstein, Peter G Pappas, Daniel H Kett

BMC Infect Dis· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
Annette C Reboli, Coleman Rotstein, Daniel H Kett, Michael Maschio, Shannon Cartier

Pharmacoeconomics· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit.
Luis Ostrosky-Zeichner, Peter G Pappas, Shmuel Shoham, Annette Reboli, Michelle A Barron

Mycoses· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.
Peter G Pappas, Carol A Kauffman, David Andes, Daniel K Benjamin, Thierry F Calandra, Annette C Reboli

Clin Infect Dis· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anidulafungin: a novel echinocandin for candida infections.
Pola de la Torre, Daniel K Meyer, Annette C Reboli

Future Microbiol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anidulafungin: a drug evaluation of a new echinocandin.
Jomy M Joseph, Rose Kim, Annette C Reboli

Expert Opin Pharmacother· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis.
José A Vazquez, Jennifer A Schranz, Kay Clark, Beth P Goldstein, Annette Reboli

J Acquir Immune Defic Syndr· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis